Bipartisan lawmakers moved to constrain HHS’ 340B rebate direction, introducing legislation that would formalize hospitals’ use of contract pharmacies while adding transparency and compliance requirements. The bill would also end HHS’ contested rebate pilot within a year and replace it with a national data clearinghouse intended to detect duplicate discounts. The proposal signals renewed political and operational risk for 340B stakeholders—especially contract-pharmacy-heavy hospital systems—as lawmakers push for tighter oversight of discounts that flow through the drug supply chain.